Cancer Research and Treatment10.4143/crt.2006.38.1.19200638119Increased ERCC Expression Correlates with Improved Outcome of Patients Treated with Cisplatin as an Adjuvant Therapy for Curatively Resected Gastric CancerSun Kyung Baek, Si-Young Kim, Jae Jin Lee, Yoon Wha Kim, Hwi Joong Yoon, Kyung Sam Cho,
European Journal of Cancer Supplements10.1016/s1359-6349(09)71265-02009723746543 A phase II study of adjuvant chemotherapy with docetaxel, capecitabine and cisplatin in patients with curatively resected stage IIIb and IV advanced gastric cancerM. Kang, M. Ryu, B. Ryoo, C. Kim, B. Kang, S. Lee, H. Chang, J. Lee, T. Kim, Y. Kang,
Cancer Treatment Reviews10.1016/s0305-7372(02)00124-x200329173-75Immunochemotherapy with OK-432 may improve survival for people with curatively resected gastric cancer☆☆☆★Abstracted from: Sakamoto J, Teramukai S, Nakazato H et al. Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. Journal of Immunotherapy 2002; 25: 405–12.Ilaria Panzini, Lorenzo Gianni, Davide Tassinari,
BMC Cancer10.1186/1471-2407-13-4432013131Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1Akinori Hisashige, Mitsuru Sasako, Toshifusa Nakajima,,
Gastric Cancer10.1007/s10120-015-0580-22015201182-189Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB–IV gastric cancerShinkyo Yoon, Changhoon Yoo, Min-Hee Ryu, Myoung Joo Kang, Baek-Yeol Ryoo, Sook Ryun Park, Jeong Hwan Yook, Sung Tae Oh, Moon-Won Yoo, Byung Sik Kim, Yoon-Koo Kang,,,
Lung Cancer10.1016/j.lungcan.2004.11.025200549185-94Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancerMunehisa Imaizumi,
International Journal of Clinical Oncology10.1007/s10147-009-0877-4200914285-89Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysisKoji Oba,,
Journal of Surgical Oncology10.1002/jso.210962008982130-134Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapyJuan J. Grau, Miguel Caballero, Mariano Monzó, Carmen Muñoz-García, Jose Domingo-Domenech, Alfons Navarro, Carlos Conill, Marc Campayo, Jose A. Bombí,
Annals of Oncology10.1093/annonc/mdz373201930vi78Interpretation the Results of Adjuvant Chemotherapy in Curatively Resected Pancreatic CancerLi-Tzong Chen,,,
Oncology10.1159/0000779992004663226-233Low Thymidylate Synthase Expression in the Primary Tumor Predicts Favorable Clinical Outcome in Resected Gastric Cancer Patients Treated with Adjuvant TegafurJuan J. Grau, Josep Domingo-Domenech, Vanesa Morente, Manuel Pera, Juan C. Garcia-Valdecasas, Josep Fuster, Antoni Bombí, Begoña Mellado, Joan Albanell, Pere Gascón,